| Peter Alan Chambré |
Peter Alan Chambré is currently the Chairman at Cancer Research Technology Ltd., 7TM A, Immatics US, Inc., Immatics NV, 7tm. Holding ApS, Cancer Research UK, and Our Future Health Uk. He previously served as the Chief Executive Officer at MedImmune Ltd., Consort Medical Ltd., and Cambridge Antibody Technology Group Ltd. He was also the Chairman at ApaTech Ltd., Immatics Biotechnologies GmbH, Xellia Pharmaceuticals AS, OneMed AB, Touchstone Innovations Ltd., Spectris Plc, and BTG Ltd. Additionally, he held positions as an Independent Non-Executive Director at Touchstone Innovations Ltd., Spectris Plc, and BTG Ltd. He has also worked as an Advisor at 3i Group Plc and as a Principal at Unilever Plc and Bain & Co., Inc. Furthermore, he served as the Chief Operating Officer at Celera Group. Mr. Chambré is a Trustee at Cancer Research UK and has an undergraduate degree from The University of Reading. |
| Daniel Lübberstedt |
Currently, Daniel Lübberstedt occupies the position of Vice President-Information Technology of Immatics NV. |
| Cedrik M. Britten |
Cedrik M. Britten is currently the Chief Medical Officer at Immatics Biotechnologies GmbH and Immatics NV. Previously, he held the position of VP & Head-Oncology Cell Therapy Research at GSK Plc from 2015 to 2020 and Vice President-Research & Development at BioNTech RNA Pharmaceuticals GmbH from 2010 to 2015. He has a graduate and doctorate degree from The Johannes Gutenberg University of Mainz. |
| Carsten Reinhardt |
Carsten Reinhardt is currently the Director at Revitope Oncology, Inc., the Non-Executive Director at Theolytics Ltd., and the Chief Development Officer at Immatics NV. He previously held positions such as Head-Clinical Development at Immatics Biotechnologies GmbH, Chief Medical Officer at Immatics US, Inc., and SVP-Clinical Development at Micromet AG. He was also a Member of the American Society of Clinical Oncology, American Society of Hematology, European Society for Medical Oncology, and Association For Cancer Immunotherapy. Reinhardt's education includes a doctorate and undergraduate degree from Ludwig-Maximilians-Universität München. |
| Steffen Walter |
Steffen Walter founded Immatics US, Inc. in 2015, where he is working as Chief Scientific Officer from 2015. Dr. Walter also currently works at Immatics Biotechnologies GmbH, as Chief Technology Officer from 2020 and Immatics NV, as Chief Operations Officer from 2023. Dr. Walter received his doctorate degree from Eberhard Karls Universität Tübingen. |
| Rainer Kramer |
Rainer Kramer is currently the Director at Immatics US, Inc. He also holds positions as the Chief Business Officer at Immatics Biotechnologies GmbH and Immatics NV. Additionally, he is a Member-Supervisory Board at iOmx Therapeutics AG. Previously, he held positions as the Principal at Amgen, Inc., Head-Business Development at MorphoSys AG, Vice President-Business Development at Shire Orphan Therapies GmbH, and Chief Business Officer at Signature Diagnostics AG. Dr. Kramer received his undergraduate degree from the University of Regensburg and his doctorate from the Max Planck Institute of Neurobiology. |
| Arnd Christ |
Arnd Christ is the founder of Cf Port GmbH. He currently holds the position of Chief Financial Officer at Immatics Biotechnologies GmbH and Immatics NV. Previously, he served as Finance Director at Avery Dennison Corp., Hoechst AG, and Avery Dennison GmbH. He also held the role of Chief Financial Officer at MediGene AG, Vivoryon Therapeutics NV, NovImmune SA, Proteros biostructures GmbH, and EleGene AG. Additionally, he was the Chief Financial Officer at InflaRx NV until 2020. Mr. Christ has also served as a Member-Supervisory Board at Immunocore Holdings Plc. He obtained an MBA from Boston University and Wuerzburg Schweinfurt University of Applied Sciences. |
| Toni Weinschenk |
Toni Weinschenk is the founder of Immatics Biotechnologies GmbH, which was founded in 2000. He held the title of Chief Innovation Officer at the company. He is also the founder of Immatics US, Inc., which was founded in 2015, where he holds the title of Chief Technology Officer. Currently, Dr. Weinschenk is the Chief Innovation Officer at Immatics NV, starting in 2020. Dr. Weinschenk obtained a doctorate degree from Eberhard Karls Universität Tübingen. |
| Harpreet Singh-Jasuja |
Harpreet Singh-Jasuja is the founder of Immatics Biotechnologies GmbH, founded in 2000, where he currently holds the title of Chief Executive Officer. He is also the founder of Immatics US, Inc., founded in 2015, where he currently holds the title of President & Chief Executive Officer. Additionally, he is the founder of Immatics NV, founded in 2000, where he currently holds the title of Chief Executive Officer, Executive Director & MD. Dr. Singh-Jasuja has an education background from Eberhard Karls Universität Tübingen, where he obtained undergraduate and doctorate degrees. |
| Evelyn Roth-Geissler |
Evelyn Roth-Geissler currently works at Immatics NV, as Vice President & Global Head-Clinical Operations from 2023. |
